EA201500943A1 - Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов - Google Patents

Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов

Info

Publication number
EA201500943A1
EA201500943A1 EA201500943A EA201500943A EA201500943A1 EA 201500943 A1 EA201500943 A1 EA 201500943A1 EA 201500943 A EA201500943 A EA 201500943A EA 201500943 A EA201500943 A EA 201500943A EA 201500943 A1 EA201500943 A1 EA 201500943A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
mobilization
reproduction
methods
stem cells
Prior art date
Application number
EA201500943A
Other languages
English (en)
Inventor
Давид Бар-Ор
Грег Томас
Original Assignee
Ампио Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ампио Фармасьютикалс, Инк. filed Critical Ампио Фармасьютикалс, Инк.
Publication of EA201500943A1 publication Critical patent/EA201500943A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Abstract

В изобретении предложены составы, которые ускоряют мобилизацию, хоуминг, размножение и/или дифференцировку стволовых клеток, а также способы их применения для лечения млекопитающих.
EA201500943A 2013-03-15 2014-03-17 Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов EA201500943A1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361791623P 2013-03-15 2013-03-15
US201361832713P 2013-06-07 2013-06-07
US201361897449P 2013-10-30 2013-10-30
US201461923314P 2014-01-03 2014-01-03
US201461939625P 2014-02-13 2014-02-13
PCT/US2014/030538 WO2014145729A2 (en) 2013-03-15 2014-03-17 Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same

Publications (1)

Publication Number Publication Date
EA201500943A1 true EA201500943A1 (ru) 2016-08-31

Family

ID=51538532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500943A EA201500943A1 (ru) 2013-03-15 2014-03-17 Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов

Country Status (17)

Country Link
US (3) US9808454B2 (ru)
EP (1) EP2968315B1 (ru)
JP (1) JP6588005B2 (ru)
KR (1) KR20150132508A (ru)
CN (1) CN105101965B (ru)
AU (1) AU2014232728B2 (ru)
BR (1) BR112015020469A2 (ru)
CA (1) CA2906864A1 (ru)
EA (1) EA201500943A1 (ru)
HK (1) HK1214143A1 (ru)
IL (1) IL240473A0 (ru)
MX (1) MX2015010937A (ru)
NZ (1) NZ712630A (ru)
PH (1) PH12015502048A1 (ru)
SG (2) SG11201506267XA (ru)
WO (1) WO2014145729A2 (ru)
ZA (1) ZA201507291B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
PT2537524T (pt) 2003-05-15 2016-09-05 Ampio Pharmaceuticals Inc Tratamento de doenças mediadas pela célula t
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
EP2765968A4 (en) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc IMPLANTABLE MEDICAL DEVICES HAVING INCREASED IMMUNE TOLERANCE, AND METHODS OF MANUFACTURING AND IMPLANTATION
MY167804A (en) 2011-10-10 2018-09-26 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
JP6231484B2 (ja) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 鼻炎の処置
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6723222B2 (ja) * 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES
US20190183900A1 (en) 2016-03-09 2019-06-20 University Of Ulsan Foundation For Industry Cooperation Composition for proliferation, differentiation promotion, or senescence inhibition of stem cells, containing jak1 inhibitor as active ingredient
AU2017235446A1 (en) * 2016-03-16 2018-11-08 Cell Medicine, Inc. Mesenchymal stem cells with enhanced efficacy
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN107418934B (zh) * 2016-05-24 2021-01-01 南开大学 Tnfsf15蛋白在人脐带血造血干细胞体外扩增中的用途
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN106834223B (zh) * 2017-04-05 2020-03-27 上海逍鹏生物科技有限公司 诱导脐带间充质干细胞向软骨细胞分化的方法
CN112094804A (zh) * 2019-06-18 2020-12-18 中国医学科学院基础医学研究所 一种异质性干细胞群、其制备方法及用途
CN111073857A (zh) * 2019-12-30 2020-04-28 深圳爱生再生医学科技有限公司 一种治疗关节炎的干细胞生物制品及其制备方法与应用
KR102545746B1 (ko) * 2020-12-03 2023-06-20 가톨릭대학교 산학협력단 유도만능줄기세포 유래 혈관세포 및 SDF1a를 발현하는 중간엽 줄기세포를 포함하는 심장 재생용 조성물
CN112657048B (zh) * 2021-01-26 2024-04-02 南方科技大学 一种非手性磁控微型机器人及其制备方法和应用
CN114209814B (zh) * 2021-12-15 2024-02-23 南开大学 Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途
CN114717184B (zh) * 2022-05-05 2023-04-21 中国水产科学研究院北戴河中心实验站 一种牙鲆精原干细胞培养液及建立牙鲆精原干细胞系的方法

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941790A (en) 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
FR2092556A5 (ru) 1970-04-02 1972-01-21 Snam Progetti
GB1353304A (en) 1971-03-30 1974-05-15 Sagami Chem Res Process for production of diketopiperazine dihydroxamates and intermediate therefor
US4006261A (en) 1973-09-28 1977-02-01 Firmenich S.A. Flavoring with mixtures of theobromine and cyclic dipeptides
US3928330A (en) 1973-12-19 1975-12-23 Ciba Geigy Corp Substituted piperazinedione carboxylic acids and metal salts thereof
GB1459488A (en) 1974-03-19 1976-12-22 Wyeth John & Brother Ltd Piperazinedione derivatives
US4088649A (en) 1975-07-02 1978-05-09 Firmenich S.A. Process for preparing a diketo-piperazine
JPS5225019A (en) 1975-08-19 1977-02-24 New Zealand Inventions Dev Production of serum albumin
US4205057A (en) 1978-01-17 1980-05-27 Government Of The United States Cerebrospinal fluid protein fragments
DE2940654A1 (de) 1979-10-06 1981-04-16 Bayer Ag, 5090 Leverkusen Dimeres keten der 1,2,,-triazol-3-carbonsaeure
US4331595A (en) 1980-06-23 1982-05-25 Ortho Pharmaceutical Corporation Immunoregulatory diketopiperazine compounds
US4289759A (en) 1980-06-23 1981-09-15 Ortho Pharmaceutical Corporation Immunoregulatory diketopiperazine compounds
JPS5836225U (ja) 1981-08-31 1983-03-09 株式会社東芝 金属製平パレツト
JPS5973574A (ja) 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
US4694061A (en) 1983-10-12 1987-09-15 Ciba-Geigy Corporation Radiation-sensitive polycondensates, processes for their preparation coated material and its use
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
JPS61112060A (ja) 1984-11-02 1986-05-30 Fujisawa Pharmaceut Co Ltd ピペラジン化合物
US4806538A (en) 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
CS254868B1 (cs) 1985-06-11 1988-02-15 Jiri Vanzura Způsob výroby cyklických dipeptidů
JPS6236331A (ja) 1985-08-12 1987-02-17 Kenji Suzuki 抗感染症剤ならびに免疫賦活剤
US4771056A (en) 1985-08-29 1988-09-13 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US4661500A (en) 1985-08-29 1987-04-28 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US5047401A (en) 1985-09-09 1991-09-10 Board Of Regents, The University Of Texas System Use of dipeptide alkyl esters to treat GVHD
US4694081A (en) 1985-09-23 1987-09-15 Monsanto Company Process to prepare 2,5-diketopiperazines
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
JPS63290868A (ja) 1987-05-22 1988-11-28 Fujisawa Pharmaceut Co Ltd ジケトピペラジン誘導体およびその塩類
JPS6413075A (en) 1987-07-03 1989-01-17 Nippon Chemiphar Co Production of 2, 5-piperazinedione derivative
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US5144073A (en) 1988-08-31 1992-09-01 Hubbs John C Process for preparation of dipeptides
US4992552A (en) 1988-08-31 1991-02-12 Eastman Kodak Company Process for preparation of amino acids
JP2001055340A (ja) 1988-10-31 2001-02-27 Welfide Corp アルブミン製剤の製造方法
US5238938A (en) 1989-02-10 1993-08-24 Otsuka Pharmaceutical Co., Ltd. Indole derivatives
DE3906952A1 (de) 1989-03-04 1990-09-06 Boehringer Mannheim Gmbh (3-(c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)6(pfeil abwaerts)-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)8(pfeil abwaerts))alkansulfinyl- und sulfonyl-2-methoxymethyl-propyl)-(2-trimethylammonio-ethyl) phosphate, verfahren zu deren herstellung diese verbindungen enthaltende arzneimittel
US5902790A (en) 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
EP0422282B1 (en) 1989-10-13 1995-04-05 Phobos N.V. Process for the continuous production of high molecular weight polyester resin
JPH03176478A (ja) 1989-12-05 1991-07-31 Snow Brand Milk Prod Co Ltd 新規なジケトピペラジン誘導体及びこれを有効成分とする免疫抑制剤
HUT60712A (en) 1990-03-15 1992-10-28 Nutrasweet Co Process for producing aspartame from diketopiperazine and process for producing intermediates
US6180616B1 (en) 1990-05-10 2001-01-30 Atsuo F. Fukunaga Use of purine receptor agonists to alleviate or normalize physiopathologically excited sensory nerve function
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
JP3266612B2 (ja) 1990-11-14 2002-03-18 ザ ユニバーシティー カンパニー プロプライエタリーリミテッド 多発性硬化症の診断および治療
US5776892A (en) 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
JPH04234374A (ja) 1990-12-27 1992-08-24 Ajinomoto Co Inc ジケトピペラジン誘導体の製造方法
GB9102997D0 (en) 1991-02-13 1991-03-27 Pfizer Ltd Therapeutic agents
US5543503A (en) 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
US5538993A (en) 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
JPH07503456A (ja) 1991-10-28 1995-04-13 サイトラン・リミテッド 医薬的ジペプチド組成物およびその使用法
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
JPH05163148A (ja) 1991-12-18 1993-06-29 Kanebo Ltd 抗腫瘍剤
GB9200210D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US5418218A (en) 1992-07-10 1995-05-23 The University Of Maryland At Baltimore Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5648486A (en) 1992-07-13 1997-07-15 Cytomed, Inc. Compounds and methods for the treatment of inflammatory and immune disorders
US5358938A (en) 1992-07-13 1994-10-25 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
AU5016793A (en) 1992-08-20 1994-03-15 Cytomed, Inc Dual functional anti-inflammatory and immunosuppressive agents
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
RU2137131C1 (ru) 1992-12-18 1999-09-10 Молекьюлар Ар-Экс, Инк. Гибридная клеточная линия (варианты), препарат антител (варианты), способ диагностики рассеянного склероза у человека (варианты), способ лечения человека, полипептид
ES2068742B1 (es) 1993-02-11 1995-11-16 Uriach & Cia Sa J Nuevos derivados de piridinio.
AU6359594A (en) 1993-03-04 1994-09-26 Cytoven International N.V. Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
JPH09503749A (ja) 1993-07-23 1997-04-15 エルエックスアール バイオテクノロジー インコーポレイテッド アポトーシスおよび関連した状態の処置方法
GB9324872D0 (en) 1993-12-03 1994-01-19 Univ Pasteur Pharmaceutical compounds
IL112627A0 (en) 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
JP2921731B2 (ja) 1994-03-10 1999-07-19 日清製油株式会社 有機溶媒または油脂類のゲル化剤
FR2717484A1 (fr) 1994-03-16 1995-09-22 Pf Medicament Nouveaux composés pseudo-bis-peptidiques analogues de la CCK, leur procédé de préparation, leur utilisation à titre de médicament et les compositions pharmaceutiques les comprenant .
GB9410387D0 (en) 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
AU2871195A (en) 1994-06-23 1996-01-19 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
US5990112A (en) 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
KR100276570B1 (ko) 1994-06-27 2001-02-01 사이토메드 인코포레이티드 심혈관질환염증성질환및면역성질환치료용화합물
US5792776A (en) 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
CA2196215C (en) 1994-07-29 2000-08-15 Shigeyuki Tasaka 1,4-dihydropyridine compound and pharmaceutical composition containing the same
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
WO1996011009A1 (en) 1994-10-05 1996-04-18 Cari Loder Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
ES2087038B1 (es) 1994-11-07 1997-03-16 Uriach & Cia Sa J Nuevas piperidinas con actividad antagonista del paf.
CZ280726B6 (cs) 1994-11-16 1996-04-17 Galena, A.S. Pentapeptidické prekurzory biologicky účinných cyklických dipeptidů
WO1996016947A1 (fr) 1994-12-01 1996-06-06 Toyama Chemical Co., Ltd. Nouveau derive de 2,3-dicetopiperazine ou sel de celui-ci
JP3634891B2 (ja) 1995-04-06 2005-03-30 株式会社海洋バイオテクノロジー研究所 キチナーゼ阻害物質
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US5811241A (en) 1995-09-13 1998-09-22 Cortech, Inc. Method for preparing and identifying N-substitued 1,4-piperazines and N-substituted 1,4-piperazinediones
US5665714A (en) 1995-12-07 1997-09-09 Clarion Pharmaceuticals Inc. N-substituted glycerophosphoethanolamines
US6060452A (en) 1996-03-13 2000-05-09 Cytran, Inc. Analogs of L-Glu-L-Trp having pharmacological activity
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038011A1 (en) 1996-04-03 1997-10-16 Pepresearch A/S Non-dendritic backbone peptide carrier
AU715667B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0904072A4 (en) 1996-04-12 2003-07-30 Peptide Technology Pty Ltd METHODS FOR TREATING IMMUNOPATHOLOGIES USING POLYUNSATURATED FATTY ACIDS
US5932579A (en) 1996-06-18 1999-08-03 Affymax Technologies N.V. Collagenase-1 and stromelysin-1 inhibitors, pharmaceutical compositions comprising same and methods of their use
US5985581A (en) 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
WO1998009968A1 (en) 1996-09-09 1998-03-12 Novartis Animal Health Australasia Pty. Limited Terpenylated diketopiperazines, (drimentines)
NZ335544A (en) 1996-10-04 2001-08-31 Neuronz Ltd Use of GPE (tripeptide or dipeptide) in form of Gly-Pro-Glu or Gly-Pro or Pro-Glu as a neuromodulator
RU2125728C1 (ru) 1996-10-10 1999-01-27 Пермская государственная медицинская академия Способ иммунодиагностики рассеянного склероза
EP0835660A1 (en) 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US6441172B1 (en) 1996-11-07 2002-08-27 Torrey Pines Institute For Molecular Studies Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US5932112A (en) 1996-11-27 1999-08-03 Browning Transport Management, Inc. Method and apparatus for killing microorganisms in ship ballast water
RU2112242C1 (ru) 1996-12-09 1998-05-27 Пермская государственная медицинская академия Способ диагностики рассеянного склероза
JPH10226615A (ja) 1997-02-18 1998-08-25 Pola Chem Ind Inc アスパラギン酸フェニルアラニン環状ジペプタイド誘導体を含有する組成物
JPH10245315A (ja) 1997-03-05 1998-09-14 Pola Chem Ind Inc シクロジペプタイド誘導体を含有する組成物
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
AU6465798A (en) 1997-03-14 1998-09-29 Neuromark Diagnosing neurologic disorders
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
RU2128840C1 (ru) 1997-06-16 1999-04-10 Пермская государственная медицинская академия Способ диагностики рассеянного склероза
US6222029B1 (en) 1997-08-01 2001-04-24 Genset 5′ ESTs for secreted proteins expressed in brain
US5834032A (en) 1997-08-11 1998-11-10 Song; Moon K. Compositions and methods for treating diabetes
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
EP0939124A3 (en) 1998-02-24 2001-03-21 Smithkline Beecham Plc MGBP1 sequences
WO1999049865A1 (en) 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
WO1999051256A2 (en) 1998-04-03 1999-10-14 Cytran, Ltd. Use of l-glu-l-trp in the treatment of hiv infection
AU3467099A (en) 1998-04-03 1999-10-25 Cytran Ltd. Methods for production of therapeutic cytokines
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
WO2000020840A1 (en) 1998-10-02 2000-04-13 Ischemia Technologies, Inc. Tests for the rapid evaluation of ischemic states and kits
US6461875B1 (en) 1998-10-02 2002-10-08 Ischemia Technologies, Inc. Test for rapid evaluation of ischemic states and kit
US6475743B1 (en) 1998-10-02 2002-11-05 Ischemia Technologies, Inc. Marker useful for detection and measurement of free radical damage and method
WO2000020454A1 (en) 1998-10-02 2000-04-13 Diagnostic Markers, Inc. Methods and materials for detection and measurement of free radical damage
US6492179B1 (en) 1998-10-02 2002-12-10 Ischemia Techologies, Inc. Test for rapid evaluation of ischemic states and kit
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
EP1166781A4 (en) 1999-01-20 2002-08-21 Kyowa Hakko Kogyo Kk PROTEASOME INHIBITORS
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000057187A2 (en) 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6090780A (en) 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
US6689765B2 (en) 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
JP2000327575A (ja) 1999-05-26 2000-11-28 Teika Seiyaku Kk ジケトピペラジン誘導体含有炎症疾患治療剤および新規なジケトピペラジン誘導体
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
WO2001034586A2 (en) 1999-11-12 2001-05-17 Wyeth Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-ht1a activity
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US20050096323A1 (en) 1999-11-30 2005-05-05 Novoscience Pharma Inc. Diketopiperazine derivatives to inhibit thrombin
JP4683810B2 (ja) 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
DE10019879A1 (de) 2000-04-20 2001-10-25 Degussa Verfahren zur Herstellung von 2,5-Diketopiperazinen, neue 2,5-Diketopiperazine und deren Verwendung
CN100522949C (zh) 2000-05-09 2009-08-05 安新药物开发股份有限公司 哌嗪二酮类化合物
US7288545B2 (en) 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
DE10026998A1 (de) 2000-05-31 2001-12-13 Fresenius Kabi De Gmbh Verfahren zur Herstellung einer kosmetischen Zusammensetzung, die humanes Serum Albumin umfasst, welches aus transgenen nicht-menschlichen Säugern erhalten wurde
EP1289990A1 (en) 2000-06-08 2003-03-12 Lilly Icos LLC Tetracyclic diketopierazine compounds as pdev inhibitors
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc FIBROSIS MODULATION METHOD
CZ20002680A3 (cs) 2000-07-21 2002-03-13 Ev®En Ing. Csc. Kasafírek Cyklické alkylthiopeptidy
CZ20002681A3 (cs) 2000-07-21 2002-03-13 Ev®En Ing. Csc. Kasafírek Cyklické tyrosinové dipeptidy
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US6967202B2 (en) 2000-08-04 2005-11-22 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
WO2002062797A2 (en) 2000-12-29 2002-08-15 Celltech R & D, Inc. Pharmaceutical uses and synthesis of diketopiperazines
GB2372740A (en) 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
AU2002225219A1 (en) 2001-01-26 2002-08-06 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis
DE60214701T2 (de) 2001-04-13 2007-09-13 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von c-jun-n-terminalen-kinasen (jnk) und anderen proteinkinasen
EP1408986B1 (en) 2001-05-08 2008-09-24 Yale University Proteomimetic compounds and methods
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
WO2003032809A2 (en) 2001-10-15 2003-04-24 The Medstar Research Institute Modulation of akt-dependent response to prevent restenosis
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
IL161733A0 (en) 2001-11-02 2005-11-20 Insert Therapeutics Inc Methods and compositions for therapeutic use of rna interference
GB0128108D0 (en) 2001-11-23 2002-01-16 Astrazeneca Ab Therapeutic use
EP1445323B1 (en) 2001-12-27 2011-01-26 Ajinomoto Co., Inc. Process for producing glutamic acid derivatives
AU2002358163A1 (en) 2002-01-18 2003-07-30 Unilever Plc Cosmetic compositions comprising a cyclodipeptide compound
CA2480832A1 (en) 2002-04-05 2003-10-23 Nitromed, Inc. Nitric oxide donors, compositions and methods of use
ES2204294B2 (es) 2002-07-02 2005-02-01 Universidade De Santiago De Compostela Nuevos antibioticos activos frente al vibrio anguillarum y sus aplicaciones en cultivos de peces, crustaceos, moluscos y otras actividades de acuicultura.
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2003302721B2 (en) 2002-08-02 2009-10-08 Beyondspring Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
KR20050042146A (ko) 2002-08-06 2005-05-04 아플라겐 게엠베하 결합 분자
DE10238144A1 (de) 2002-08-15 2004-02-26 Basf Ag Verwendung von Diketopiperazin-Derivaten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
AU2003270087B2 (en) 2002-09-03 2009-04-23 Georgetown University Akt inhibitors, pharmaceutical compositions, and uses thereof
DK1571970T3 (da) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
US7196169B2 (en) 2002-10-11 2007-03-27 Queen's University At Kingston Isolated post-translationally modified mammalian proteins for monitoring and diagnosing muscle damage
JP2006515574A (ja) 2002-11-22 2006-06-01 ノボ・ノルデイスク・エー／エス 肥満症の治療に使用される化合物
PT2537524T (pt) 2003-05-15 2016-09-05 Ampio Pharmaceuticals Inc Tratamento de doenças mediadas pela célula t
CN101279094A (zh) * 2003-05-15 2008-10-08 Dmi生物科学公司 T-细胞介导的疾病的治疗
CA2533901A1 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
JP4842817B2 (ja) 2003-09-03 2011-12-21 ニューレン ファーマシューティカルズ リミテッド 神経保護二環式化合物およびその使用方法
JP2008505084A (ja) 2004-06-29 2008-02-21 アムゲン インコーポレイティッド フラノピリミジン
PT1786273T (pt) 2004-08-20 2019-02-19 The American Nat Red Cross Esquemas de isolamento e purificação de proteínas sequenciais por cromatografia de afinidade
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
CA2597456A1 (en) 2005-02-14 2006-08-31 Merck & Co., Inc. Inhibitors of akt activity
CN101309709A (zh) 2005-09-21 2008-11-19 苏尔莫迪克斯公司 包含天然生物可降解的多糖的涂层和物品
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MX2008013216A (es) 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
US20080017576A1 (en) 2006-06-15 2008-01-24 Rensselaer Polytechnic Institute Global model for optimizing crossflow microfiltration and ultrafiltration processes
AR061240A1 (es) 2006-06-20 2008-08-13 Lilly Co Eli Compuestos de de 4-isoquinolin-fenol,composiciones farmaceuticas que los contienen y su uso como agentes antineoplasicos y/o antivirales.
JP2009542813A (ja) 2006-07-11 2009-12-03 ハルクネスス プハルマセウティカルス，インコーポレイテッド 飽食因子を使用して肥満を治療する方法
US8231929B2 (en) 2006-11-09 2012-07-31 Cook Medical Technologies Llc Medical device coating process
EP2173352B1 (en) 2007-07-12 2016-09-07 University of South Florida Inhibitors of akt/pkb with anti-tumor activity
US20090038416A1 (en) 2007-08-07 2009-02-12 Aleta Behrman Bonner System and method for biological sample collection and analyte detection
WO2009032651A1 (en) 2007-08-31 2009-03-12 Smithkline Beecham Corporation Inhibitors of akt activity
EP2203051A4 (en) 2007-09-25 2011-09-07 Abbott Lab OCTAHYDROPENTAL COMPOUNDS AS CHEMOKIN RECEPTOR ANTAGONISTS
US20090163936A1 (en) 2007-12-21 2009-06-25 Chunlin Yang Coated Tissue Engineering Scaffold
US20100042206A1 (en) 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
WO2009114725A2 (en) * 2008-03-12 2009-09-17 Children's Hospital Medical Center Mobilization of hematopoietic stem cells
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
JP2012502655A (ja) * 2008-09-22 2012-02-02 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ（エイ・スター） 軟骨形成前駆細胞の分化を改良する方法
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2791847C (en) 2009-03-04 2017-05-02 Mannkind Corporation An improved dry powder drug delivery system
CN105567699A (zh) 2009-10-30 2016-05-11 诺维信生物制药丹麦公司 白蛋白变体
CN101914490B (zh) * 2010-08-13 2012-10-10 中国医科大学 一种人羊膜间充质干细胞无血清培养基及其培养方法
CN103200952B (zh) 2010-09-07 2016-04-06 安皮奥制药股份有限公司 疾病的治疗
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
WO2012045094A1 (en) * 2010-10-01 2012-04-05 The Trustees Of Columbia University In The City Of New York Derivation of fibrochondrocytes from progenitor cells
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MY167804A (en) 2011-10-10 2018-09-26 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
EP2765968A4 (en) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc IMPLANTABLE MEDICAL DEVICES HAVING INCREASED IMMUNE TOLERANCE, AND METHODS OF MANUFACTURING AND IMPLANTATION
JP6231484B2 (ja) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 鼻炎の処置
JP3176478U (ja) 2012-04-11 2012-06-21 ネイス株式会社 運動用エアートランポリン
EA030414B1 (ru) 2013-02-01 2018-08-31 Ампио Фармасьютикалс, Инк. Способы получения дикетопиперазинов и соединений, содержащих дикетопиперазины
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6723222B2 (ja) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド 関節病態の治療
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES

Also Published As

Publication number Publication date
EP2968315A4 (en) 2016-08-31
US20180153880A1 (en) 2018-06-07
PH12015502048A1 (en) 2016-01-18
US20220016110A1 (en) 2022-01-20
US11026940B2 (en) 2021-06-08
CA2906864A1 (en) 2014-09-18
HK1214143A1 (zh) 2016-07-22
AU2014232728B2 (en) 2019-02-21
US20140286913A1 (en) 2014-09-25
CN105101965A (zh) 2015-11-25
MX2015010937A (es) 2015-10-29
NZ712630A (en) 2021-07-30
KR20150132508A (ko) 2015-11-25
JP2016515533A (ja) 2016-05-30
JP6588005B2 (ja) 2019-10-09
AU2014232728A1 (en) 2015-10-29
ZA201507291B (en) 2019-04-24
SG11201506267XA (en) 2015-09-29
BR112015020469A2 (pt) 2020-01-28
US9808454B2 (en) 2017-11-07
CN105101965B (zh) 2021-03-09
EP2968315A2 (en) 2016-01-20
IL240473A0 (en) 2015-09-24
EP2968315B1 (en) 2020-06-03
SG10201707619RA (en) 2017-10-30
WO2014145729A2 (en) 2014-09-18
WO2014145729A3 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891532A1 (ru) Композиции и способы лечения гемоглобинопатий
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
MD3827845T2 (ro) Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201892147A1 (ru) Бициклические соединения
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201591615A1 (ru) Замещенные ксантины и способы их применения
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
EA201891251A1 (ru) Бициклические ингибиторы pad4